Drug
E7389 LF
E7389 LF: highest development phase Phase 1/2, developed by Eisai. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Eisai
Trials
| Drug | Phase | Indication |
|---|---|---|
| E7389-LF NCT04078295 | Phase 1/2 | Solid Neoplasms |
Latest
No recent events.
Follow E7389 LF on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.